Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Chemotherapy + Cemiplimab vs Cemiplimab in Older/Frail Metastatic NSCLC
NCT07020065Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, pemetrexed, gemcitabine and Paclitaxel Micelles for Injection in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression-Free Survival at 1 year. Started Apr 2026; status: recruiting.
02
Drugs
carboplatinpemetrexedgemcitabinePaclitaxel Micelles for Injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07020065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020065.